TREATMENT OF THROMBOSIS BY COMBINED USE OF A FACTOR XA INHIBITOR AND ASPIRIN, TISSUE PLASMINOGEN ACTIVATOR (TPA), A GPIIB/IIIA ANTAGONIST, LOW MOLECULAR WEIGHT HEPARIN OR HEPARIN - Patent 1161279

(19)

(11)

EP 1 161 279 A1

(12)

(43)	Date of publication:
	12.12.2001 Bulletin 2001/50

(21)	Application number: 00913894.2

(22)	Date of filing: 10.03.2000

(51)	International Patent Classification (IPC)⁷: A61P 7/02, A61P 9/12, A61K 31/715, A61K 45/06, A61K 38/49, A61K 38/02, A61K 31/42, A61K 31/60 // A61K38:49, A61K31:415, A61K38:02, A61K31:415,(A61K45/06, 31:715), A61K31:415, A61K31:60, A61K31:415, A61K31:42, A61K31:415

(86)	International application number:
	PCT/US0006/451

(87)	International publication number:
	WO 0053/264 (14.09.2000 Gazette 2000/37)

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
	Designated Extension States:
	LT LV RO SI

(30)

Priority:

11.03.1999 US 123815 P

(71)	Applicant: Du Pont Pharmaceuticals Company
	Wilmington, DE 19807 (US)

(72)	Inventor:
	WONG, Pancras, C. Wilmington, DE 19808 (US)

(74)	Representative: Howard, Paul Nicholas et al
	Carpmaels & Ransford43 Bloomsbury Square London WC1A 2RA London WC1A 2RA (GB)

(54)	TREATMENT OF THROMBOSIS BY COMBINED USE OF A FACTOR XA INHIBITOR AND ASPIRIN, TISSUE PLASMINOGEN ACTIVATOR (TPA), A GPIIB/IIIA ANTAGONIST, LOW MOLECULAR WEIGHT HEPARIN OR HEPARIN